Last reviewed · How we verify
NCT04994990
Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles
NA trial testing OnabotulinumtoxinA Standard Dose in Rhytides. Withdrawn.
30 November 2024
Quick facts
| Lead sponsor | Northwell Health |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Start date | 25 May 2023 |
| Primary completion | 30 November 2024 |
| Estimated completion | 30 May 2025 |
Drugs / interventions tested
- OnabotulinumtoxinA Standard Dose — full drug profile →
- OnabotulinumtoxinA Half Standard Dose — full drug profile →
Conditions studied
- Rhytides — all drugs for Rhytides →
Sponsor
Northwell Health — full company profile →
Who can join
Adults 18 to 65, any sex, with Rhytides. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research is being done to determine if lower doses of botox than what is currently recommended can give similar results to patients, at lower cost and lower risk to them. Subjects will receive botox in the same areas of the upper face with standard doses on one side of the face. On the other side, double the botox concentration will be administered, free of charge to the participant, in order to see if the difference in concentration creates a difference in wrinkle reduction and participant satisfaction over time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04994990
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rhytides
Currently open trials in the same condition.
- NCT04162496 — Restylane Refyne for Correction of Horizontal Neck Rhytides · NA · active not recruiting
Other Northwell Health trials
Trials by the same sponsor.
- NCT07253662 — Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Aden · Phase 1 · recruiting
- NCT07191041 — Emotional Urinary Tract Infection · not yet recruiting
- NCT07254091 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer · EARLY_PHASE1 · recruiting
- NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
- NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04994990 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwell Health
- Last refreshed: 16 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04994990.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing